Wu ZX - Search Results

1

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression.

Pan Z, Wang K, Wang X, Jia Z, Yang Y, Duan Y, Huang L, Wu ZX, Zhang JY, Ding X. Pan Z, et al. Among authors: wu zx. Mol Cancer. 2022 Mar 18;21(1):77. doi: 10.1186/s12943-022-01547-3. Mol Cancer. 2022. PMID: 35303882 Free PMC article.

2

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Wu ZX, Teng QX, Cai CY, Wang JQ, Lei ZN, Yang Y, Fan YF, Zhang JY, Li J, Chen ZS. Wu ZX, et al. Biochem Pharmacol. 2019 Aug;166:120-127. doi: 10.1016/j.bcp.2019.05.015. Epub 2019 May 9. Biochem Pharmacol. 2019. PMID: 31078601

3

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study.

Ji N, Yang Y, Cai CY, Wang JQ, Lei ZN, Wu ZX, Cui Q, Yang DH, Chen ZS, Kong D. Ji N, et al. Among authors: wu zx. Front Oncol. 2019 Jun 18;9:514. doi: 10.3389/fonc.2019.00514. eCollection 2019. Front Oncol. 2019. PMID: 31275850 Free PMC article.

4

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.

Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS. Wu ZX, et al. Cancers (Basel). 2020 Jan 12;12(1):186. doi: 10.3390/cancers12010186. Cancers (Basel). 2020. PMID: 31940916 Free PMC article.

5

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, Hu C, Liao D, Zhang W, Chen ZS. Zhang L, et al. Mol Cancer. 2020 Jan 17;19(1):10. doi: 10.1186/s12943-019-1112-1. Mol Cancer. 2020. PMID: 31952518 Free PMC article.

6

Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.

Wang J, Yang DH, Yang Y, Wang JQ, Cai CY, Lei ZN, Teng QX, Wu ZX, Zhao L, Chen ZS. Wang J, et al. Among authors: wu zx. Int J Mol Sci. 2020 Feb 19;21(4):1387. doi: 10.3390/ijms21041387. Int J Mol Sci. 2020. PMID: 32092870 Free PMC article.

7

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells.

Wang J, Wang JQ, Cai CY, Cui Q, Yang Y, Wu ZX, Dong X, Zeng L, Zhao L, Yang DH, Chen ZS. Wang J, et al. Among authors: wu zx. Front Oncol. 2020 Feb 27;10:228. doi: 10.3389/fonc.2020.00228. eCollection 2020. Front Oncol. 2020. PMID: 32175279 Free PMC article.

8

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells.

Wu ZX, Peng Z, Yang Y, Wang JQ, Teng QX, Lei ZN, Fu YG, Patel K, Liu L, Lin L, Zou C, Chen ZS. Wu ZX, et al. Front Oncol. 2020 May 12;10:674. doi: 10.3389/fonc.2020.00674. eCollection 2020. Front Oncol. 2020. PMID: 32477940 Free PMC article.

9

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro.

Yang Y, Ji N, Teng QX, Cai CY, Wang JQ, Wu ZX, Lei ZN, Lusvarghi S, Ambudkar SV, Chen ZS. Yang Y, et al. Among authors: wu zx. Front Oncol. 2020 May 12;10:700. doi: 10.3389/fonc.2020.00700. eCollection 2020. Front Oncol. 2020. PMID: 32477943 Free PMC article.

10

Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.

Wu ZX, Yang Y, Wang G, Wang JQ, Teng QX, Sun L, Lei ZN, Lin L, Chen ZS, Zou C. Wu ZX, et al. Cancer Sci. 2020 Aug;111(8):2872-2882. doi: 10.1111/cas.14505. Epub 2020 Jun 29. Cancer Sci. 2020. PMID: 32478948 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

532 results

Search Page

Filters